Aytu BioPharma Inc. (AYTU)

Overview

Aytu Biopharma, Inc. is a commercial-stage pharmaceutical company that directs its efforts towards the commercialization of novel therapeutics and consumer healthcare products across the United States and internationally. Operating under two main segments, Rx and Consumer Health, Aytu Biopharma aims at addressing a variety of medical conditions through its diverse product portfolio. Initially known as Aytu BioScience, Inc., the company underwent a name change to Aytu Biopharma, Inc. in March 2021, marking a new phase in its business journey. Based in Denver, Colorado, Aytu Biopharma is committed to improving patient care by offering innovative solutions across different areas of healthcare, including ADHD treatments, allergic conditions, dietary supplements, and treatment for hair loss, among others.

Products and Services

• Adzenys XR-ODT & Cotempla XR-ODT

  Prescription products targeted at treating attention deficit hyperactivity disorder (ADHD). Adzenys XR-ODT is designed for patients six years and older, while Cotempla XR-ODT caters to patients aged six to seventeen years old.

• Karbinal ER, Poly-Vi-Flor, and Tri-Vi-Flor

  These are part of the pediatric prescription product portfolio. Karbinal ER is an extended-release suspension formulated to treat various allergic conditions in patients two years and above. Poly-Vi-Flor and Tri-Vi-Flor are complementary prescription fluoride-based multi-vitamin products. They come in liquid and chewable tablet forms, designed for infants and children suffering from fluoride deficiency.

• Regoxidine - for Men and Women

  An over-the-counter aerosol foam developed as a proprietary solution for treating hair loss in both men and women.

• OmepraCareDR and EsomepraCareDR

  These products represent Aytu Biopharma’s offerings in the digestive health category, specifically targeting frequent heartburn. They are acid reducers available over-the-counter.

• AR101 (enzastaurin)

  Currently in development, AR101 is an investigational first-in-class small molecule, serine/threonine kinase inhibitor. It aims at targeting the treatment of vascular Ehlers-Danlos Syndrome through an orally available medication.